1 / 21

Advanced Prostate Cancer Treatment Options: Insights from Urologist Alessandro Giacobbe

Explore various treatment options for advanced prostate cancer, including surgery, radiation therapy, and multimodal approaches. Understand the impact of Gleason scores on long-term cancer-specific survival rates and mortality. Learn about locally advanced prostate cancer management strategies recommended by experts in the field.

tbishop
Download Presentation

Advanced Prostate Cancer Treatment Options: Insights from Urologist Alessandro Giacobbe

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Categorie di rischio: punto di vista dell’urologo Alessandro Giacobbe Ospedale “San Giovanni Bosco” S.C. Urologia Torino

  2. “Advanced” PCa

  3. Treatment Options • Surgery • RT • Cryo/Other • Multimodal Approach

  4. Treatment Options • Surgery • RT • Cryo/Other • MultimodalApproach

  5. 10-yr PCSM >80%

  6. 15-yr Radical Prostatectomy CancerSpecificMortality Gleason score≤6 15-yr Cancer specific Survival ≥99% Gleason score 7(3+4) 15-yr Cancer specific Survival 98% Gleason score 7(4+3) 15-yr Cancer specific Survival 94% Gleason score 8-10 15-yr Cancer specific Survival 65%

  7. 15-yr Radical Prostatectomy Cancer Specific Mortality Gleason score≤6 15-yr Cancer specific Survival ≥99% Gleason score 7(3+4) 15-yr Cancer specific Survival 98% Gleason score 7(4+3) 15-yr Cancer specific Survival 94% Gleason score 8-10 15-yr Cancer specific Survival 65%

  8. Locally Advanced CaP Gerber, G.S., et al.. Eur Urol, 1997. 32: 385 Hsu, C.Y., et al. Eur Urol, 2007. 51: 121 Joniau, S., et al. Eur Urol, 2015. 67: 319 Xylinas, E., et al. BJU Int, 2009. 103: 1173

  9. Locally Advanced CaP Gerber, G.S., et al.. Eur Urol, 1997. 32: 385 Hsu, C.Y., et al. Eur Urol, 2007. 51: 121 Joniau, S., et al. Eur Urol, 2015. 67: 319 Xylinas, E., et al. BJU Int, 2009. 103: 1173

  10. Locally Advanced CaP Gerber, G.S., et al.. Eur Urol, 1997. 32: 385 Hsu, C.Y., et al. Eur Urol, 2007. 51: 121 Joniau, S., et al. Eur Urol, 2015. 67: 319 Xylinas, E., et al. BJU Int, 2009. 103: 1173

  11. Treatment Options • Surgery • RT • Cryo/Other • MultimodalApproach

  12. 2.5 fold increased risk of metastasis

  13. Treatment Options • Surgery • RT • Cryo/Other • MultimodalApproach

  14. Treatment Options • Surgery • RT • Cryo/Other • MultimodalApproach

  15. Adjuvant RT recommended for pT3 pts

  16. OurClinicalPractice • Age <70, Gleason ≤ 6, PSA < 10 • Nervesparingprostatectomy • ActiveSurveillance (1-2 poscore/12 or more) • Gleason score 7 or PSA >10 • Age <70 RadProstatectomy and PLND • Age >70 Radiotherapy • Gleason score ≥8 • Surgery + Radiotherapy + ADT (intermittent)

More Related